Can I read Significant Benefits of Osimertinib Against Adenosquamous Carcinoma Harboring Germline T790M Mutation on EtoBox?

Significant Benefits of Osimertinib Against Adenosquamous Carcinoma Harboring Germline T790M Mutation by Ran Huo; Jinghua Li; Xiaofang Li; Junping Shi; Kunjie Wang; Jin Jiao; Yanhong Shang is a Medicine article available to read on EtoBox.

What is Significant Benefits of Osimertinib Against Adenosquamous Carcinoma Harboring Germline T790M Mutation about?

## Abstract ## Background The identification of epidermal growth factor receptor (EGFR) mutations represents a milestone in the treatment of advanced non-small cell lung cancer. Patients with lung adenosquamous carcinomas (ASCs) rarely present with germline EGFR T790M mutation. The optimal treatment for cancers with germline EGFR T790M mutation (especially ASC) is not clear. ## Materials and Methods Using next-generation sequencing, we tested 450 cancer-related genes in a 27-year-old patient's lung adenosquamous carcinoma and matched blood samples. Germline mutations in samples from the patient's available relatives were identified by Sanger sequencing. ## Results We identified germline EGFR T790M mutation in the patient's lung adenosquamous carcinoma. He was treated with osimertinib and achieved complete response for more than 30 months, without significant drug-related adverse events. Genetic testing showed that germline EGFR T790M mutation might be a characteristic of inherited lung cancer. ## Conclusion Osimertinib can be a treatment option for patients with lung ASC harboring germline EGFR T790M mutation. ## Key Points A patient with adenosquamous carcinoma harboring a germlin

Who reads Significant Benefits of Osimertinib Against Adenosquamous Carcinoma Harboring Germline T790M Mutation?

Author

Ran Huo; Jinghua Li; Xiaofang Li; Junping Shi; Kunjie Wang; Jin Jiao; Yanhong Shang

Publisher

Oxford University Press (OUP)

Published

2020

Language

EN

Field

Medicine (Health Sciences)